Amylyx Pharma edges up despite pulling Relyvrio from market
Amylyx Pharmaceuticals’ (Nasdaq: AMLX) shares were up 5.9% at $2.78 mid-morning, despite the company revealing that it was pulling its lead product from the market after the drug failed in a confirmatory trial that was announced last month. At that time Amylyx lost around 80% of its capitalization.
The Massachusetts, USA-based said it has started a process with the US Food and Drug Administration (FDA) and Health Canada to voluntarily discontinue the marketing authorizations for its amyotrophic lateral sclerosis (ALS) drug Relyvrio/Albrioza (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine] from the respective markets
Relyvrio/Albrioza will no longer be available for new patients as of today. Patients currently on therapy in the USA and Canada who, in consultation with their physician, wish to stay on treatment can be transitioned to a free drug program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze